Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report
- 17 September 2025
- journal article
- case report
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-4
Abstract
Purpose Tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, is used to treat lymphoplasmacytic lymphoma (LPL). A hallmark complication of LPL is hyperviscosity syndrome (HVS), caused by markedly elevated serum IgM levels. Plasma exchange (PE) is a standard treatment for HVS but may also remove circulating drugs, particularly those with high protein binding, potentially reducing drug exposure and efficacy. Evaluating the impact of PE on the pharmacokinetics of drugs used to treat LPL is important for optimal treatment. Methods We report the case of a 63-year-old man with LPL who presented with acute headache and was diagnosed with HVS. Tirabrutinib (480 mg, once daily) was initiated, and PE was performed the next day because of persistent IgM elevation. To assess the impact of PE on tirabrutinib plasma concentrations, blood samples were collected approximately 3 h prior to PE (C15), immediately before PE (C18), and immediately after PE (C20). Results The concentrations at C15, C18 and C20 were 33.3, 16.9, and 11.4 ng/mL, respectively. The elimination rate constant (ke) was calculated as 0.226 h⁻¹ before PE and 0.197 h⁻¹ during PE. Based on the pre-PE ke, the predicted post-PE concentration (C20) assuming no PE was approximately 10.6 ng/mL, slightly lower than the observed value. Conclusion PE appeared to have minimal impact on the tirabrutinib plasma concentration, likely due to its large volume of distribution. Although further cases are needed, this case supports the feasibility of concomitant PE during tirabrutinib therapy without significant compromise of drug efficacy.Keywords
This publication has 12 references indexed in Scilit:
- Effect of therapeutic plasma exchange on antimicrobials in critically ill patientsCritical Care, 2024
- Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignanciesInternational Journal of Hematology, 2022
- Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RAClinical Pharmacology & Therapeutics, 2021
- Managing toxicities of Bruton tyrosine kinase inhibitorsHematology-American Society Hematology Education Program, 2020
- Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphomaNeuro-Oncology, 2020
- Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom MacroglobulinemiaFrontiers in Oncology, 2020
- Tirabrutinib: First ApprovalDrugs, 2020
- Targeting Bruton's tyrosine kinase in B cell malignanciesNature Reviews Cancer, 2014
- Evidence-based focused review of management of hyperviscosity syndromeBlood, 2012
- Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study.2007